Tokyo Tape
Sign in
← OncoTherapy Science

Quarterly report · Q3

4564.TEDINET S100Q6XE
Period2022-04-01 → 2022-12-31
Filed2023-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks10 of 10 passed
Key figures · 32
MetricValuePeriodScopeSource row
Revenue¥700m2022-04-01 → 2022-12-31Cons.Net sales
Revenue¥335m2021-04-01 → 2021-12-31Cons.Net sales
Operating income−¥905m2022-04-01 → 2022-12-31Cons.Operating income
Operating income−¥1.7bn2021-04-01 → 2021-12-31Cons.Operating income
Ordinary income−¥929m2022-04-01 → 2022-12-31Cons.Ordinary income
Ordinary income−¥2.1bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥1.7bn2021-04-01 → 2021-12-31Cons.Ordinary income
Profit before tax−¥912m2022-04-01 → 2022-12-31Cons.Income before income taxes
Profit before tax−¥2.1bn2021-04-01 → 2021-12-31Cons.Income before income taxes
Net income (owners)−¥913m2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)−¥2.6bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥2.1bn2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent
Net income−¥913m2022-04-01 → 2022-12-31Cons.Profit loss
Net income−¥2.1bn2021-04-01 → 2021-12-31Cons.Profit loss
Total assets¥1.4bnat 2022-12-31Cons.Assets
Total assets¥2.7bnat 2022-03-31Cons.Assets
Total assets¥2.9bnat 2021-12-31Cons.Total assets (5-year summary)
Total liabilities¥392mat 2022-12-31Cons.Liabilities
Total liabilities¥705mat 2022-03-31Cons.Liabilities
Net assets / equity¥1.1bnat 2022-12-31Cons.Net assets
Net assets / equity¥2.0bnat 2022-03-31Cons.Net assets
Net assets / equity¥2.4bnat 2021-12-31Cons.Net assets (5-year summary)
Cash and deposits¥978mat 2022-12-31Cons.Cash and deposits
Cash and deposits¥1.8bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥-4.742022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-1.552022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-13.722021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-11.522021-04-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-4.732021-10-01 → 2021-12-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio68.1%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio70.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio80.5%at 2021-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 29
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥172,000
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥172,000
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥290m
jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥691m
jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥691m
jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segmentsegment profit2022-04-01 → 2022-12-31−¥79m
jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue2022-04-01 → 2022-12-31¥9m
jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue external2022-04-01 → 2022-12-31¥9m
jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥172,000
jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentsegment profit2022-04-01 → 2022-12-31−¥536m
—segment totalrevenue2022-04-01 → 2022-12-31¥700m
—segment totalrevenue external2022-04-01 → 2022-12-31¥700m
—segment totalrevenue intersegment2022-04-01 → 2022-12-31¥172,000
—segment totalsegment profit2022-04-01 → 2022-12-31−¥615m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-12-31−¥8m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-12-31−¥8m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-12-31−¥282m
jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥337m
jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥329m
jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥8m
jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segmentsegment profit2021-04-01 → 2021-12-31−¥127m
jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue2021-04-01 → 2021-12-31¥7m
jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue external2021-04-01 → 2021-12-31¥7m
jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥132,000
jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentsegment profit2021-04-01 → 2021-12-31−¥1.3bn
—segment totalrevenue2021-04-01 → 2021-12-31¥344m
—segment totalrevenue external2021-04-01 → 2021-12-31¥335m
—segment totalrevenue intersegment2021-04-01 → 2021-12-31¥8m
—segment totalsegment profit2021-04-01 → 2021-12-31−¥1.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 322
ItemContextValueUnit
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember-8465000JPY
Transactions with other segmentsPrior1YTDDuration－JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember6710000JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember336969000JPY
Net salesPrior1YTDDuration_ReportableSegmentsMember343679000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember-8465000JPY
Net salesPrior1YTDDuration335214000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q3r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember-1301540000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q3r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember-126961000JPY
Operating incomePrior1YTDDuration_ReportableSegmentsMember-1428501000JPY
Operating incomePrior1YTDDuration_ReconcilingItemsMember-281813000JPY
Operating incomePrior1YTDDuration-1710315000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q3r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember8666000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q3r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember691023000JPY
Revenues from external customersCurrentYTDDuration_ReportableSegmentsMember699689000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration699689000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q3r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember172000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q3r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_ReportableSegmentsMember172000JPY
Transactions with other segmentsCurrentYTDDuration_ReconcilingItemsMember-172000JPY
Transactions with other segmentsCurrentYTDDuration－JPY
Net salesCurrentYTDDuration_jpcrp040300-q3r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember8838000JPY
Net salesCurrentYTDDuration_jpcrp040300-q3r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember691023000JPY
Net salesCurrentYTDDuration_ReportableSegmentsMember699862000JPY
Net salesCurrentYTDDuration_ReconcilingItemsMember-172000JPY
Net salesCurrentYTDDuration699689000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q3r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember-536143000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q3r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember-79300000JPY
Operating incomeCurrentYTDDuration_ReportableSegmentsMember-615443000JPY
Operating incomeCurrentYTDDuration_ReconcilingItemsMember-289504000JPY
Operating incomeCurrentYTDDuration-904947000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2023-02-13
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第22期第３四半期（自　2022年10月１日　至　2022年12月31日）
Company name cover pageFilingDateInstant
Original text (Japanese)オンコセラピー・サイエンス株式会社
Company name in english cover pageFilingDateInstantOncoTherapy Science, Inc.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　　嶋田　順一
Address of registered headquarter cover pageFilingDateInstantText · Plus
Telephone number address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)044－201－6429（2023年１月１日より本店移転に伴い電話番号を変更しております。）
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)管理本部長　水越　潤一
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)神奈川県川崎市川崎区東田町１番地２
Telephone number nearest place of contact cover pageFilingDateInstant
Original text (Japanese)044－201－6429（2023年１月１日より本店移転に伴い電話番号を変更しております。）
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)管理本部長　水越　潤一
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE05363
Fund codeFilingDateInstant－
Security codeFilingDateInstant45640

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 10 of 10 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass